Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey


Creative Commons License

Ozmen V., Atasoy A., GÖKMEN E., Ozdogan M., Guler N., URAS C., ...More

CUREUS, vol.8, no.3, 2016 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Article
  • Volume: 8 Issue: 3
  • Publication Date: 2016
  • Doi Number: 10.7759/cureus.522
  • Journal Name: CUREUS
  • Keywords: breast cancer, adjuvant treatment, oncotype dx, decision impact, genomic testing, INTERNATIONAL EXPERT CONSENSUS, BREAST-CANCER, PRIMARY THERAPY, RECOMMENDATIONS, CHEMOTHERAPY, WOMEN, ASSAY, MANAGEMENT, EXPRESSION, PATTERNS

Abstract

Introduction: Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX (R) 21-gene assay is predictive of distant recurrence in ER-positive, HER2-negative early breast cancer. We aimed to evaluate the impact of the Recurrence Score (R) (RS) on treatment decisions and physician perceptions in Turkey. We also studied correlations between RS and routine risk factors.